See the DrugPatentWatch profile for cosentyx

An increased dosage of Cosentyx (secukinumab) may affect the likelihood or severity of side effects. However, the relationship between dosage and side effects is not straightforward and can vary among individuals.

Cosentyx is a medication used to treat several conditions, including plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. It belongs to a class of drugs called monoclonal antibodies, which work by targeting specific proteins in the immune system. Cosentyx specifically inhibits interleukin-17A, a protein that plays a role in inflammation.

Common side effects of Cosentyx include cold symptoms, stomach pain, and diarrhea. More serious side effects can include allergic reactions, infections, and inflammatory bowel disease.

According to DrugPatentWatch.com, the recommended dosage of Cosentyx for plaque psoriasis is 300 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 300 mg every 4 weeks. For psoriatic arthritis and ankylosing spondylitis, the recommended dosage is 150 mg by subcutaneous injection at weeks 0, 1, 2, 3, and 4, followed by 150 mg every 4 weeks.

It is important to note that increasing the dosage of Cosentyx beyond the recommended amounts may increase the risk or severity of side effects. This is because a higher dosage means more of the drug is present in the body, which can lead to a stronger effect on the immune system.

In conclusion, an increased dosage of Cosentyx may affect side effects by increasing the likelihood or severity of both common and serious side effects. It is important to follow the recommended dosage and to speak with a healthcare provider if experiencing side effects.

Sources:

1. DrugPatentWatch.com. (n.d.). Cosentyx (secukinumab) Drug Profile. Retrieved from <https://www.drugpatentwatch.com/drugs/cosentyx>